Participation of global scholars and internal core researchers, disclosure of latest research results and commercialization roadmap, presentation of peptide-based core pipeline development performance, clinical plan, and global technology transfer and commercialization strategy
D&D Pharmatech (347850) will hold 'D&D Pharmatech R&D Day 2026' on November 3 and reveal the research and development achievements of its peptide-based core pipeline, future clinical plans, and global technology transfer and commercialization strategies.
D&D Pharmatech (CEO Seol-gi Lee), a company specializing in the development of GLP-1 new drugs, announced on the 14th that it will hold this event at the Grand Intercontinental Seoul Parnas in Samseong-dong, Seoul. The event will be held from 10:30 am to 3:10 pm for major stakeholders such as institutional investors, analysts, and media.
This event consists of a morning academic session by global scholars linked to the core pipeline and an afternoon session where executives present R&D achievements and business strategies. After examining the latest research trends in the basic science field, we plan to continue the discussion with the company's major pipeline development status, future clinical plans, and global commercialization strategies.
In the morning, distinguished scholars in the fields of neurodegenerative diseases and radiopharmaceuticals, including the co-founders of D&D Pharmatech, will introduce the latest research results and the possibility of developing new drugs. The first speaker, Ted M. Dawson, director of the Cell Engineering Research Institute at Johns Hopkins University School of Medicine, will give a presentation on the topic of 'Discovering targets and biomarkers for degenerative brain diseases based on single cell genomics and AI.'
Next, Professor Valina L. Dawson of Johns Hopkins University School of Medicine will give a lecture on the topic 'Targeted treatment of neuroinflammation in Parkinson's disease: from mechanism identification to NLY01 and beyond.' The mechanism of action and clinical significance of D&D Pharmatech's major degenerative brain disease pipeline will be explained.
The final presentation of the morning session will be given by Martin G. Pomper, chair of the Department of Radiology at UT Southwestern Medical Center. Professor Pomper, co-founder of Z-Alpha, a radiopharmaceutical affiliate of D&D Pharmatech, introduces the possibility of using radiopharmaceuticals in the field of cancer and central nervous system diseases and the latest clinical research and development trends under the theme of 'Radiopharmaceuticals in new drug development: Cases of application to the cancer and central nervous system'.
In the afternoon, D&D Pharmatech executives will announce the development results of major pipelines and future business strategies. Director Eunji Park, head of the R&D Division, explains the latest research and development achievements and future clinical plans for major new drug candidates, including the peptide-based core pipeline, through 'D&D Pharmatech R&D Update'.
Next, Kwak Jeong-heon, head of the business development team, shares the status of global technology transfer and joint development under the theme of 'D&D Pharmatech Business Development Update'. It will also present commercialization strategies for major pipelines and directions for expanding global partnerships.
Lastly, CEO Seol-gi Lee announces mid- to long-term growth strategies and major business directions to leap forward as a global biotech company. Based on the clinical development progress of the core pipeline and global business development results, we plan to build a foundation for sustainable growth and share strategies to increase corporate value. After each presentation, a question and answer session will be held to discuss major research and development achievements and future vision with attendees.
CEO Seol-gi Lee said, "This R&D Day event is a meaningful opportunity to highlight the new scientific possibilities of new drug development, which is the foundation of the company, with global scholars, while sharing the peptide new drug development capabilities accumulated by D&D Pharmatech and the specific results of the core pipeline." He added, "Based on the research and development results accumulated so far, we will accelerate the clinical development of major pipelines and expand global partnerships."
He added, "We will continue to increase the value of our pipeline through differentiated technology and systematic development strategies and grow into an innovative new drug development company with competitiveness in the global market."
